HomeCompareAPTO vs SBUX

APTO vs SBUX: Dividend Comparison 2026

APTO yields 116.96% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APTO wins by $7.45M in total portfolio value
10 years
APTO
APTO
● Live price
116.96%
Share price
$1.71
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.61M
Annual income
$2,839,061.37
Full APTO calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — APTO vs SBUX

📍 APTO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPTOSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APTO + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
APTO pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APTO
Annual income on $10K today (after 15% tax)
$9,941.52/yr
After 10yr DRIP, annual income (after tax)
$2,413,202.16/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, APTO beats the other by $2,352,736.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APTO + SBUX for your $10,000?

APTO: 50%SBUX: 50%
100% SBUX50/50100% APTO
Portfolio after 10yr
$3.89M
Annual income
$1,455,098.92/yr
Blended yield
37.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

APTO
Analyst Ratings
10
Buy
1
Hold
Consensus: Buy
Altman Z
-114.1
Piotroski
3/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APTO buys
0
SBUX buys
0
No recent congressional trades found for APTO or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPTOSBUX
Forward yield116.96%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$7.61M$167.0K
Annual income after 10y$2,839,061.37$71,136.45
Total dividends collected$6.91M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: APTO vs SBUX ($10,000, DRIP)

YearAPTO PortfolioAPTO Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$22,396$11,695.91$11,121$420.68+$11.3KAPTO
2$48,444$24,480.41$12,548$648.40+$35.9KAPTO
3$101,324$49,488.77$14,440$1,013.98+$86.9KAPTO
4$205,154$96,737.39$17,068$1,617.30+$188.1KAPTO
5$402,568$183,053.76$20,912$2,649.52+$381.7KAPTO
6$766,451$335,702.65$26,875$4,499.29+$739.6KAPTO
7$1,417,434$597,331.71$36,771$8,014.12+$1.38MAPTO
8$2,549,060$1,032,405.58$54,542$15,197.11+$2.49MAPTO
9$4,462,671$1,735,176.87$89,602$31,242.49+$4.37MAPTO
10$7,614,120$2,839,061.37$167,011$71,136.45+$7.45MAPTO

APTO vs SBUX: Complete Analysis 2026

APTOStock

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Full APTO Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this APTO vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APTO vs SCHDAPTO vs JEPIAPTO vs OAPTO vs KOAPTO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.